Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N

被引：0

作者：

Jacquelyn Smith

Mark D. Robida

Krista Acosta

Bharathi Vennapusa

Amita Mistry

Greg Martin

Alton Yates

H. James Hnatyszyn

机构：

[1] Ventana Medical Systems Inc.,Companion Diagnostics Pharma Services, Assay Development

[2] Roche Tissue Diagnostics,Companion Diagnostics Pharma Services, Pathology Office

[3] Ventana Medical Systems Inc.,Companion Diagnostics, Project Management Office

[4] Roche Tissue Diagnostics,Companion Diagnostics, Pharma Services, Clinical Services Management

[5] Ventana Medical Systems Inc.,Companion Diagnostics Pharma Services, CDx CAP/CLIA Lab Operations

[6] Roche Tissue Diagnostics,undefined

[7] Ventana Medical Systems Inc.,undefined

[8] Roche Tissue Diagnostics,undefined

[9] Ventana Medical Systems Inc.,undefined

[10] Roche Tissue Diagnostics,undefined

来源：

Diagnostic Pathology | / 11卷

关键词：

PD-L1; IHC; NSCLC; SP263; E1L3N;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] PD-L1 status by SP142 and sp263 immunohistochemistry in triple-negative breast cancer
Cordoba, A.
Mercado, M. D. R.
Amat, I.
Beloqui, R.
Aguiar, B.
Rodriguez, Y.
Guerrero-Setas, D.
VIRCHOWS ARCHIV, 2020, 477 : S44 - S44
[22] A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade
Cortellini, Alessio
Zampacorta, Claudia
De Tursi, Michele
Grillo, Lucia R.
Ricciardi, Serena
Bria, Emilio
Martini, Maurizio
Giusti, Raffaele
Filetti, Marco
Dal Mas, Antonella
Russano, Marco
Dall'Olio, Filippo Gustavo
Buttitta, Fiamma
Marchetti, Antonio
PATHOLOGICA, 2024, 116 (04) : 222 - 231
[23] Assessment of heterogeneity of PD-L1 expression in NSCLC, HNSCC, and UC with Ventana SP263 assay.
Scott, Marietta L.
Scorer, Paul
Lawson, Nicola
Ratcliffe, Marianne J.
Barker, Craig
Rebelatto, Marlon
Walker, Jill
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[24] Precision and Repeatability of the VENTANA PD-L1 (SP263) Assay Across Six Different Tumor Types
Nielsen, Alma
Manriquez, Guadalupe
Hayden, Dorothy
Lian, Fangru
Liu, Chunyan
Patil, Pallavi
Wang, Peiyi
Gu, Pengfei
Schnittker, Karina
Roland, Bryan
Quiroz, Michelle
Newell, Amy Hanlon
LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 830 - 831
[25] Pitfalls of PD-L1 Immunohistochemistry: A Comparison of 22C3 and SP263 antibodies Across Laboratories and Pathologists
Wilberger, Adam
Aisner, Dara
Merrick, Daniel T.
MODERN PATHOLOGY, 2018, 31 : 756 - 757
[26] Interobserver agreement of PD-L1 (SP263) assessment in advanced NSCLC on cytological smears and histological samples
Ambrosi, Francesca
Giunchi, Francesca
Capizzi, Elisa
Cancellieri, Alessandra
Trisolini, Rocco
Ardizzoni, Andrea
Fiorentino, Michelangelo
Ricci, Costantino
PATHOLOGY RESEARCH AND PRACTICE, 2022, 233
[27] Precision and Repeatability of the VENTANA PD-L1 (SP263) Assay Across Six Different Tumor Types
Nielsen, Alma
Manriquez, Guadalupe
Hayden, Dorothy
Lian, Fangru
Liu, Chunyan
Patil, Pallavi
Wang, Peiyi
Gu, Pengfei
Schnittker, Karina
Roland, Bryan
Quiroz, Michelle
Newell, Amy Hanlon
MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 830 - 831
[28] Pitfalls of PD-L1 Immunohistochemistry: A Comparison of 22C3 and SP263 antibodies Across Laboratories and Pathologists
Wilberger, Adam
Aisner, Dara
Merrick, Daniel T.
LABORATORY INVESTIGATION, 2018, 98 : 756 - 757
[29] External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different
Dodson, Andrew
Parry, Suzanne
Lissenberg-Witte, Birgit
Haragan, Alex
Allen, David
O'Grady, Anthony
McClean, Emma
Hughes, Jamie
Miller, Keith
Thunnissen, Erik
JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2020, 6 (02): : 138 - 145
[30] PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays
Dabbagh, Tamara Z.
Sughayer, Maher A.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (06) : 462 - 466

← 1 2 3 4 5 →